AlzeCure enters the next development phase with ACD857 for Alzheimer's disease
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has begun a preclinical development phase with the company's drug candidate ACD857.
ACD857 is being developed within AlzeCure's NeuroRestore platform, with the aim of developing symptom-relieving drugs for the treatment of diseases with cognitive disorders. The preclinical development program with ACD857 includes preclinical safety and tolerability studies but also formulation work and stability testing. ACD857 may play a significant role in the treatment of indications in which cognitive functions are impaired, such as Alzheimer's disease.
“We are very pleased to have started the preclinical development with ACD857. We thereby build on the communicated strategy to strengthen the project portfolio with the development of several candidates in parallel and also show AlzeCure's capacity for development and delivery. It's amazing to see how the Discovery and Development organization has performed over the past year with the ability to run both preclinical and clinical programs,” said Martin Jönsson, CEO of AlzeCure Pharma AB.
- Related Links